Heghine Khachatryan: Emerging Evidence Links NET Formation to Thrombosis and Disease Progression in Gynecologic Malignancies
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared
Jim Hoffman’s post on LinkedIn:
“NETosis and Thrombosis in Gynecologic Malignancies: An Emerging Link Between Inflammation and Cancer.
Neutrophil extracellular traps (NETs) have emerged as key mediators at the intersection of inflammation, malignancy, and thrombosis.
In gynecologic cancers, NETosis contributes not only to tumor progression, metastatic dissemination, and therapeutic resistance but also plays a pivotal role in the pathogenesis of cancer-associated thrombosis.
NETs provide a highly prothrombotic scaffold that promotes platelet activation, endothelial dysfunction, and coagulation cascade amplification, thereby increasing the risk of venous thromboembolism (VTE).
Growing evidence suggests that elevated NET formation in ovarian, endometrial, and cervical cancers correlates with more aggressive disease phenotypes, poorer clinical outcomes, and a heightened thrombotic burden.
Beyond their pathogenic role, NET-associated biomarkers are increasingly being investigated as potential tools for risk stratification, disease monitoring, and the development of targeted therapeutic strategies.
As our understanding evolves, NETosis is becoming recognized as a critical mechanistic bridge linking cancer, inflammation, and thrombosis.
Targeting NET formation may represent a promising future approach for reducing both tumor progression and thrombotic complications in patients with gynecologic malignancies.”
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Naina Kumar, published in Clinical and Translational Oncology, adding:
“NETs exhibit a dual role in gynecological cancers, contributing to tumor progression and therapy resistance while also presenting valuable diagnostic and therapeutic opportunities.
Their components—NE, MPO, CitH3, cfDNA, and ctDNA are emerging as promising biomarkers for disease monitoring and prognosis.
Targeting NETs through DNase therapy, PAD4 inhibition, ROS modulation, or immune regulation holds potential to enhance treatment efficacy and support personalized management of gynecological cancers.”
Title: Neutrophil extracellular traps (NETosis) in gynecologic cancers: from pathogenesis to therapeutic opportunities: a narrative review
Authors: Naina Kumar
Stay updated on all scientific advances Hemostasis Today.
-
Jun 21, 2026, 07:24Seema Dawood: The Power of Blood Smear Confirmation in Detecting Immature Granulocytes
-
Jun 21, 2026, 05:32Flora Peyvandi: Characterizing Acquired VWD Through a Large Patient Cohort
-
Jun 21, 2026, 05:23Mohammed Alo: The Gap Between Nattokinase Marketing and Evidence
-
Jun 21, 2026, 05:11Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar N63
-
Jun 21, 2026, 04:00X. Long Zheng: New Findings on ADAMTS13 in Hemostasis and Thrombosis
-
Jun 21, 2026, 03:04Mauricio Vasco Ramirez: Balancing Bleeding and Thrombotic Risks in Ultrasound-Guided Intervention
-
Jun 21, 2026, 02:30Megan Adediran: Standing Together for Sickle Cell Awareness and Care
-
Jun 20, 2026, 22:23Bringing Conversations About Stroke and Men’s Health to the Melbourne Storm Community – Stroke Foundation
-
Jun 20, 2026, 21:03Johannes Grillari: Post-Stroke Senescence May Be More Adaptive Than Previously Thought